Transform Cell Selection with BubbleGen™
Simplifying cell therapy research workflows with microbubble technology
FEATURED KIT
Introducing the
BubbleGen™ CD3+ Cell
Selection Kit
The first commercial product in the BubbleGen™ portfolio for T cell isolation is now available.
- Ready-to-use reagents
- Up to 1 billion total input cells
- Magnetic bead-free workflow
Cell Therapy Research Requires a
New Approach to Cell Selection
Cell selection is a critical step in cell therapy research, but traditional magnetic bead-based approaches introduce complexity, limit flexibility, and create challenges for scale-up. Multi-step processing, specialized equipment, proprietary consumables, and the potential for magnetic residuals can add operational bottlenecks that can slow timelines.
BubbleGen™ offers a new approach.
Built on Bracco’s lipid microbubble technology, BubbleGen™ enables simpler, bead-free, and column-free cell selection that integrates seamlessly into cell therapy research workflows.
As Featured In
Solving Key Cell Selection Challenges
BubbleGen™ streptavidin-conjugated microbubble cell selection technology overcomes the limitations of traditional magnetic bead-based technologies to support the evolving needs of cell therapy research.
Traceless
Cells are released by "popping" the bubbles through gas exchange for efficient selection.
Eliminate Magnetic Residuals
The bead-free BubbleGen™ technology reduces process risk associated with magnetic bead carryover.
Streamline Research Workflows
Reduce research workflow complexity with a beadfree, column-free process that eliminates the need for specialized magnetic separation equipment.
Simplify Integration
BubbleGen™ is designed to work with existing cell therapy research processes and is compatible with a wide range of platforms and modalities.
Flexible Cell Targeting
Built on a universal streptavidin backbone, BubbleGen™ can be paired with biotinylated antibodies to target virtually any cell population and supports positive, negative, and sequential cell selection.
Scale with Confidence
Integrate seamlessly with fully open, automation ready microbubble technology designed for closed, end to end systems.
Built to Drive Cell Therapies Research
Bracco has made significant investments in infrastructure to support the cell therapy field, including its newly unveiled GMP ready manufacturing facility in Geneva, Switzerland.
Learn more
Let’s Discuss your Research Workflow.
Every cell therapy research process is different. Partner with our team to identify how BubbleGen™ can help address your cell selection challenges and support your research program goals.
Purpose-Built for Cell Therapy Research Workflows
Flexible cell selection and activation solutions
Cell therapy research workflows are evolving rapidly, creating new challenges in cell enrichment and research process scalability. Researchers need cell selection technologies that can adapt to different targets, simplify processing and support research programs.
BubbleGen™ cell selection solutions provide a flexible, bead-free approach designed to help overcome these challenges and accelerate timelines while still maintaining the cell quality and performance needed for cell therapy research applications.
Contact our team to explore our bead-free approach to cell selection and activation.
-
The BubbleGen™ CD3+ Cell Selection Kit is designed to streamline the isolation of CD3+ T cells using Bracco's microbubble technology.
Obtain high-purity, high-quality, functional T cells to support downstream research processes.
Let’s Discuss Your Research Workflow.
Every cell therapy research process is different. Partner with our team to identify how BubbleGen™ can help address your cell selection challenges and support your research program goals.
Bracco’s Cell Selection and Activation Microbubbles at a Glance
Antibody-Driven Targeting
Biotinylated antibody driven targeting enables precise selection of a wide range of immune cell subsets (e.g., CD3, CD4, CD8, TCR γ/δ, CD34).
T Cell Activation
Achieve T cell selection and activation simultaneously with Bracco’s microbubbles.
Traceless
Cells are released by “popping” the bubbles through gas exchange for efficient selection.
Cell Selection and Activation Microbubble Overview
Lipid microbubbles composed of phospholipids, streptavidin, and a gas core bind biotinylated antibodies targeting cell surface markers (e.g. CD3+, CD4+, CD8+).
Bracco’s Cell Selection and Activation Microbubbles are Lyophilized
Lyophilized microbubbles are stable for up to 3 years at 4°C and 3 months post-reconstitution at 4°C.
The Cell Selection and Activation Process
with Bracco’s Microbubbles
Let’s Discuss Your Research Workflow.
Every cell therapy research process is different. Partner with our team to identify how BubbleGen™ can help address your cell selection challenges and support your research program goals.
BubbleGen™ Cell Selection
and Activation Research Products
Microbubble-based solutions for cell selection and activation.
The BubbleGen™ research product portfolio provides researchers with flexible tools for isolating, enriching, activating, and manipulating target cell populations.
NOW AVAILABLE
BubbleGen™ CD3+ Cell Selection Kit (RUO-grade)
Designed for isolation of CD3+ T cells from complex starting materials.
- Ready-to-use format
- Magnetic bead-free workflow
- Traceless cell release
- Compatible with downstream cell therapy research workflows
Let’s Discuss Your Research Workflow.
Every cell therapy research process is different. Partner with our team to identify how BubbleGen™ can help address your cell selection challenges and support your research program goals.
Upcoming Events
Advanced Therapies Week Europe | Barcelona, Spain
Sep 7-9, 2026
Meet with our team to see how BubbleGen™ cell selection solutions can help streamline your cell therapy research workflow by reaching out to us through the conference app or at [email protected]. Learn how our universal cell therapy microbubbles support efficient cell selection and activation while reducing complexity.
11th CAR-TCR Summit | Boston, MA
Sep 16-17, 2026
We're launching the BubbleGen™ CD3+ Cell Selection Kit at CAR-TCR!
Visit booth #25 to be among the first to experience our inaugural BubbleGen™ research product and learn how it can support T-cell enrichment for cell therapy research workflows.
Meet with our team to discuss your cell selection and activation challenges, and don't miss our presentation on Thursday September 17 at 12:20pm during the early-stage manufacturing stream.
Meeting on the Mesa | Phoenix, AZ
Oct 5–7, 2026
Let's talk strategy. Meet with our team to discuss your current cell therapy research workflow, future plans, and where innovative cell selection technologies may fit into your research program. We'd welcome the opportunity to explore how BubbleGen™ can support your cell selection and activation needs.
Advanced Therapies Week | San Diego, CA
Jan 18-21, 2027
Visit us at Bracco booth #370 to discover the growing BubbleGen™ research product portfolio and learn how our cell selection solutions are helping simplify cell therapy research workflows. Be sure to attend our Innovation Zone presentation to hear our latest technology updates (please refer to event agenda).
Latest News
BubbleGen™ in the Press
Why ex vivo CAR T still matters in the age of in vivo hype
Drug Discovery News | 24 August 2026
Next-Gen Cell Therapy Starts with the Right T Cells
BioSpectrum Asia | 19 August 2026
Regen Report | 04 July 2026
Gentler Cell Separation Methods Gain Momentum
GEN | 03 June 2026
Can Microbubbles Replace Magnetic Beads In Cell Therapy Manufacturing?
BioSpectrum Asia | 01 June 2026
Roving Reporter Asks: Where Is Real Progress Being Made in Manufacturing and Supply Chain?
The Medicine Maker | 28 May 2026
Cleanroom Technology | 06 May 2026
Advanced Therapies London 2026: Moving from ambition to application
Drug Discovery World | 06 April 2026
Bracco Investing In Geneva Facility To Scale Cell Therapy Manufacturing
Cell & Gene | 02 April 2026
Bracco enters cell-therapy space with microbubble platform
BioProcess Insider | 06 February 2026
Let’s Discuss Your Research Workflow.
Every cell therapy research process is different. Partner with our team to identify how BubbleGen™ can help address your cell selection challenges and support your research program goals.
Our Team
Sophie He, PhD
Vice President, Cell Therapy,
Head of M&A and Partnering
Research & Development, Switzerland
Thierry Bettinger, PhD
Bracco Research Center Geneva Director
Samir Cherkaoui, PhD
Novel Agents Department Manager
Sophie Montandon, PhD
Pathobiology Lab Manager
Research & Development, China
Jiemeng Li, PhD
R&D Manager
Corporate Development
Michael Godeny, PhD
Senior Director, Cell Therapy Partnerships
Marianna Mainardi Koga, PhD
Senior Manager, Cell Therapy Europe
Marisa Reinoso
Director, Cell Therapy Partnerships
Xiaojie He
Strategy and BD Manager, China
Let’s Discuss Your Research Workflow.
Every cell therapy research process is different. Partner with our team to identify how BubbleGen™ can help address your cell selection challenges and support your research program goals.
For Research Use Only. Not for Use in Humans.